|
Boehringer Ingelheim's Investigational Treatment for Cognitive Impairment Associated with Schizophrenia Receives FDA Breakthrough Therapy Designation
|
3
|
363
|
May 24, 2021
|
|
Cognition deficits
|
6
|
206
|
March 3, 2024
|
|
Boehringer's schizophrenia med boosts cognition in phase 2
|
23
|
2460
|
April 17, 2022
|
|
Boehringer provides update on iclepertin Phase III program in schizophrenia
|
1
|
68
|
January 16, 2025
|
|
New medication in the pipeline for cognitive impairment?
|
6
|
1005
|
May 22, 2016
|